Associated Genetic Biomarkers
KMT2A PTD serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain KMT2A PTD as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
Trials with KMT2A PTD in the inclusion eligibility criteria most commonly target acute myeloid leukemia .
Azacitidine, anti-cd33 monoclonal antibody bi 836858, idh2 inhibitor ag-221, samalizumab, and cytarabine are the most frequent therapies in trials with KMT2A PTD as an inclusion criteria .
Significance of KMT2A PTD in Diseases
Acute Myeloid Leukemia +
KMT2A is mutated in 1.44% of acute myeloid leukemia patients .
KMT2A PTD is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KMT2A PTD and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) .
Azacitidine, anti-cd33 monoclonal antibody bi 836858, and idh2 inhibitor ag-221 are the most frequent therapies in trials for acute myeloid leukemia that contain KMT2A PTD .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.